Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status Prescription; Discontinued
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 65129-1260; 67457-450; 63323-140; 42658-010; 54893-0115; 59605-3006; 58623-0037; 12502-4912; 0143-9871; 12502-5406; 44087-4000
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyneuropathy17.09.03.012--Not Available
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.001--Not Available
Pulmonary fibrosis22.01.02.006--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.0030.002554%
Rales22.02.04.004--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.003--Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.0040.001095%
Renal failure20.01.03.005--Not Available
Sepsis11.01.11.0030.000762%
Septic shock24.06.02.011; 11.01.11.004--Not Available
Sinusitis22.07.03.007; 11.01.13.0050.000730%
Skin cancer23.08.02.002; 16.03.02.0020.001095%Not Available
Skin disorder23.03.03.007--Not Available
Skin infection23.09.04.002; 11.01.12.003--
Skin lesion23.03.03.0100.001095%Not Available
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.0050.000730%
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.0070.001095%Not Available
Thrombocytopenia01.08.01.0020.002919%Not Available
Thrombosis24.01.01.006--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
The 6th Page    First    Pre   6 7 8 9    Next   Last    Total 9 Pages